Eatontown, NJ, August 25, 2017 --(PR.com
)-- Immunostics, a global leader in rapid diagnostic tests, announced today that it has named Scott J. Robitaille to serve as President of Sales & Marketing, effective August 28, 2017. Mr. Robitaille brings more than 20 years of experience in the medical diagnostics field, including 10 years in various senior and executive roles at Alere, Immunostics and most recently Chembio Diagnostics.
“We are pleased that Scott is returning to Immunostics, and we are eager to work with him as we position the company for the future,” said Euiyul Choi, CEO of Boditech Med Inc. “His intimate knowledge of Immunostics along with his broad experience and deep relationships in healthcare, will give us added power in the marketplace.”
During his time at Immunostics, Robitaille was instrumental in the growth of the company and in expanding its reach throughout the U.S. healthcare industry. His expertise, knowledge of the healthcare industry, relationships with major players in healthcare distribution will greatly benefit the company.
In his new role at Immunostics, Robitaille is charged with developing a domestic salesforce and marketing strategy that leverages their board product portfolio.
Immunostics is a subsidiary of Boditech Med Inc. (KOSDAQ), a world-leading innovator and provider of in vitro diagnostics equipment and reagents.
Immunostics is a leading developer and manufacturer of point-of-care diagnostics products in the United States. Founded in 1970, the Company is headquartered in Eatontown, NJ and has a state-of-the-art manufacturing facility in Eatontown. The Company has a broad portfolio of diagnostics solutions that provide more effective ways to assist in the diagnosis of disease.
Boditech Med Inc. (KOSDAQ: 206640) markets its own brand of point-of-care diagnostics products to more than 100 countries. The Boditech products (ichroma™, AFIAS™ and TRIA™) based on its fluorescence immunoassay technologies and know-how allow worldwide healthcare providers to provide fast, precise diagnosis to patients for more than a decade.